Active immunotherapy: current state of the art in vaccine approaches for NHL
ML Palomba - Current oncology reports, 2012 - Springer
Immune therapy of cancer is a rapidly evolving field, with long-deserved successes now
finally achieved. As new pathways triggered by the immune synapsis are elucidated, and …
finally achieved. As new pathways triggered by the immune synapsis are elucidated, and …
Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen
S Buchan, E Grønevik, I Mathiesen, CA King… - The Journal of …, 2005 - journals.aai.org
We have developed novel DNA fusion vaccines encoding tumor Ags fused to pathogen-
derived sequences. This strategy activates linked T cell help and, using fragment C of tetnus …
derived sequences. This strategy activates linked T cell help and, using fragment C of tetnus …
DNA fusion gene vaccines against cancer: from the laboratory to the clinic
FK Stevenson, J Rice, CH Ottensmeier… - Immunological …, 2004 - Wiley Online Library
Vaccination against target antigens expressed by cancer cells has now become a realistic
goal. DNA vaccines provide a direct link between identification of genetic markers in tumors …
goal. DNA vaccines provide a direct link between identification of genetic markers in tumors …
Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge
DNA vaccination has been widely explored to develop new, alternative and efficient
vaccines for cancer immunotherapy. DNA vaccines offer several benefits such as specific …
vaccines for cancer immunotherapy. DNA vaccines offer several benefits such as specific …
Immunotherapy of hematologic malignancy
HE Heslop, FK Stevenson… - ASH Education Program …, 2003 - ashpublications.org
Over the past few years, improved understanding of the molecular basis of interactions
between antigen presenting cells and effector cells and advances in informatics have both …
between antigen presenting cells and effector cells and advances in informatics have both …
Soluble T cell receptors: novel immunotherapies
PE Molloy, AK Sewell, BK Jakobsen - Current opinion in pharmacology, 2005 - Elsevier
T cell receptors are antigen-specific proteins that have evolved to recognize peptide
antigens presented by human leukocyte antigen molecules on most cell types. Like …
antigens presented by human leukocyte antigen molecules on most cell types. Like …
[HTML][HTML] HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection
DW Du, ZS Jia, GY Li, YY Zhou - World Journal of …, 2003 - ncbi.nlm.nih.gov
AIM: To seek for an effective method to improve the immune responses induced by DNA
vaccine expressing HBV surface antigen (pCR3. 1-S) in Balb/c mice (H-2 d). METHODS …
vaccine expressing HBV surface antigen (pCR3. 1-S) in Balb/c mice (H-2 d). METHODS …
Treatment of T-cell non-hodgkin'lymphoma
AM Evens, RB Gartenhaus - Current treatment options in oncology, 2004 - Springer
Opinion statement T-cell non-Hodgkin's lymphoma (NHL) represents approximately 10% to
15% of all lympho-mas in Western countries. Patients with T-cell NHL are often treated …
15% of all lympho-mas in Western countries. Patients with T-cell NHL are often treated …
DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice
K Kamachi, T Konda, Y Arakawa - Vaccine, 2003 - Elsevier
Pertussis toxin (PT) is the major virulence factor of Bordetella pertussis, and detoxified PT is
a crucial antigen of acellular pertussis vaccine. Here, plasmid DNA expressing the pertussis …
a crucial antigen of acellular pertussis vaccine. Here, plasmid DNA expressing the pertussis …